Skye Bioscience to Participate in SXSW Session on Obesity
Provided By GlobeNewswire
Last update: Feb 24, 2025
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dhillon, Chief Executive Officer, in a South by Southwest panel session exploring the future of obesity management beyond GLP-1 drugs.
Read more at globenewswire.com1.57
+0.14 (+9.41%)
Find more stocks in the Stock Screener
SKYE Latest News and Analysis
6 days ago - ChartmillTop stock movements in today's session.Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
6 days ago - ChartmillTuesday's session: top gainers and losersIntrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
6 days ago - ChartmillThe market is filled with gapping stocks in Tuesday's session.In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.
